000120588 001__ 120588
000120588 005__ 20240228145454.0
000120588 0247_ $$2doi$$a10.18632/oncotarget.15863
000120588 0247_ $$2pmid$$apmid:28423600
000120588 0247_ $$2pmc$$apmc:PMC5410342
000120588 0247_ $$2altmetric$$aaltmetric:19231370
000120588 037__ $$aDKFZ-2017-01017
000120588 041__ $$aeng
000120588 082__ $$a610
000120588 1001_ $$0P:(DE-HGF)0$$aWittig-Blaich, Stephanie$$b0$$eFirst author
000120588 245__ $$aSystematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma.
000120588 260__ $$a[S.l.]$$bImpact Journals LLC$$c2017
000120588 3367_ $$2DRIVER$$aarticle
000120588 3367_ $$2DataCite$$aOutput Types/Journal article
000120588 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1533215204_15323
000120588 3367_ $$2BibTeX$$aARTICLE
000120588 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120588 3367_ $$00$$2EndNote$$aJournal Article
000120588 520__ $$aNext-generation sequencing has dramatically increased genome-wide profiling options and conceptually initiates the possibility for personalized cancer therapy. State-of-the-art sequencing studies yield large candidate gene sets comprising dozens or hundreds of mutated genes. However, few technologies are available for the systematic downstream evaluation of these results to identify novel starting points of future cancer therapies.We improved and extended a site-specific recombination-based system for systematic analysis of the individual functions of a large number of candidate genes. This was facilitated by a novel system for the construction of isogenic constitutive and inducible gain- and loss-of-function cell lines. Additionally, we demonstrate the construction of isogenic cell lines with combinations of the traits for advanced functional in vitro analyses. In a proof-of-concept experiment, a library of 108 isogenic melanoma cell lines was constructed and 8 genes were identified that significantly reduced viability in a discovery screen and in an independent validation screen. Here, we demonstrate the broad applicability of this recombination-based method and we proved its potential to identify new drug targets via the identification of the tumor suppressor DUSP6 as potential synthetic lethal target in melanoma cell lines with BRAF V600E mutations and high DUSP6 expression.
000120588 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000120588 588__ $$aDataset connected to CrossRef, PubMed,
000120588 7001_ $$0P:(DE-HGF)0$$aWittig, Rainer$$b1
000120588 7001_ $$aSchmidt, Steffen$$b2
000120588 7001_ $$0P:(DE-HGF)0$$aLyer, Stefan$$b3
000120588 7001_ $$0P:(DE-He78)7999346780553d7fab7ba69d5afdfa71$$aBewerunge-Hudler, Melanie$$b4$$udkfz
000120588 7001_ $$0P:(DE-HGF)0$$aGronert-Sum, Sabine$$b5
000120588 7001_ $$0P:(DE-HGF)0$$aStrobel-Freidekind, Olga$$b6
000120588 7001_ $$aMüller, Carolin$$b7
000120588 7001_ $$aList, Markus$$b8
000120588 7001_ $$aJaskot, Aleksandra$$b9
000120588 7001_ $$aChristiansen, Helle$$b10
000120588 7001_ $$aHafner, Mathias$$b11
000120588 7001_ $$0P:(DE-HGF)0$$aSchadendorf, Dirk$$b12
000120588 7001_ $$aBlock, Ines$$b13
000120588 7001_ $$aMollenhauer, Jan$$b14
000120588 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.15863$$gVol. 8, no. 14$$n14$$p23760-23774$$tOncoTarget$$v8$$x1949-2553$$y2017
000120588 909CO $$ooai:inrepo02.dkfz.de:120588$$pVDB
000120588 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000120588 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000120588 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000120588 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7999346780553d7fab7ba69d5afdfa71$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000120588 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000120588 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000120588 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000120588 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000120588 9141_ $$y2017
000120588 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOTARGET : 2015
000120588 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120588 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120588 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120588 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120588 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120588 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120588 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000120588 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOTARGET : 2015
000120588 9201_ $$0I:(DE-He78)B050-20160331$$kB050$$lMolekulare Genomanalyse$$x0
000120588 9201_ $$0I:(DE-He78)W110-20160331$$kW110$$lMicroarray Unit$$x1
000120588 9201_ $$0I:(DE-He78)L401-20160331$$kL401$$lDKTK Essen$$x2
000120588 980__ $$ajournal
000120588 980__ $$aVDB
000120588 980__ $$aI:(DE-He78)B050-20160331
000120588 980__ $$aI:(DE-He78)W110-20160331
000120588 980__ $$aI:(DE-He78)L401-20160331
000120588 980__ $$aUNRESTRICTED